Tag Archives: Dupixent sBLA

Sanofi’s Dupixent Receives FDA Priority Review for the Treatment of Bullous Pemphigoid

(IN BRIEF) Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupixent would be the first targeted medicine for BP in the U.S., with the FDA’s decision expected … Read the full press release